Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $29,130.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00. Following the completion of the sale, the vice president now owns 34,258 shares of the company’s stock, valued at approximately $997,935.54. The trade was a 2.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Patrick Lamy also recently made the following trade(s):

• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $28,480.75.

Akero Therapeutics Trading Up 3.3 %

Shares of AKRO stock opened at $29.34 on Friday. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a market cap of $2.05 billion, a P/E ratio of -7.82 and a beta of -0.23. The company has a 50 day moving average of $30.89 and a 200-day moving average of $27.44. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Several large investors have recently added to or reduced their stakes in AKRO. SG Americas Securities LLC boosted its holdings in Akero Therapeutics by 191.2% in the 2nd quarter. SG Americas Securities LLC now owns 14,517 shares of the company’s stock worth $341,000 after buying an additional 9,532 shares during the period. Bank of New York Mellon Corp grew its position in shares of Akero Therapeutics by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after purchasing an additional 61,988 shares in the last quarter. Rhumbline Advisers boosted its stake in Akero Therapeutics by 30.3% in the 2nd quarter. Rhumbline Advisers now owns 107,338 shares of the company’s stock worth $2,518,000 after purchasing an additional 24,940 shares during the period. TD Asset Management Inc grew its holdings in Akero Therapeutics by 23.7% during the 2nd quarter. TD Asset Management Inc now owns 154,592 shares of the company’s stock valued at $3,627,000 after buying an additional 29,600 shares in the last quarter. Finally, Quest Partners LLC increased its position in shares of Akero Therapeutics by 22,021.1% during the second quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock valued at $296,000 after buying an additional 12,552 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup began coverage on Akero Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.